CHITA – a registry of in vitro NAMs
Has FDA lost it’s way with NAMs? NAMs or New Alternative Methodologies is the term used by FDA for new regulatory tools to improve predictivity and help replace, reduce and/or…
It takes courage to address common pitfalls in drug discovery and perseverance to traverse the route. In my work and as an advisor I’ve seen 100s of early-stage drug discovery…
Is coronavirus morbidity exacerbated by environmental pollution? A potential mechanism underlying thrombosis-related side effects connects multiple known risk factors. In the early days of the COVID-19 pandemic, signs that infected…
How can we incorporate human-based animal alternatives into drug discovery? Can we reduce animal testing and still improve program success? Making good decisions requires integrating information from many assays and…
A strong chain of translatability is crucial for successful drug discovery programs. The chain of translatability is a molecular-level association between the mechanisms that drive the assay phenotype, the preclinical disease…
VCAM-1 is one of our favorite biomarkers. The levels of this clinical biomarker are increased in patients with diseases as diverse as Parkinson’s disease and arthritis. The regulation of VCAM-1…
It’s not just about measuring what matters – it’s about making what you measure matter. There are many options for endpoints to measure in phenotypic assays. Endpoints to consider include…
Developing phenotypic assays that model human disease is a heavy lift. Our understanding of disease biology is limited. And there are so many variables, it’s hard to know where to…
How do we design phenotypic assays that are physiologically relevant? And what do we mean by “relevant”? For those of us working in drug discovery or chemical safety, what we…
When I started out in tissue culture of primary human cells, there were few methods available and few options for cell types. Most human cell-based assays used immortalized cell lines…
